Table 4 Inter-patient and Intra-patient variability of C min and C max for each antiretroviral agent
| Â | Â | Â | Cmin | Cmax | ||||
|---|---|---|---|---|---|---|---|---|
Antiretroviral agent | Â | n | Mean (SD) | Inter-patient CV | Intra-patient CV median (IQR) | Mean (SD) | Inter-patient CV | Intra-patient CV median (IQR) |
Atazanavir | 400 QD | 9 | 250.4 (195.4) | 78.0% | 57.4 (40.5-86.7) | 2000.4 (1145.5) | 57.3% | 61.9 (44.2-66.0) |
Atazanavir (boosted with ritonavir) | 300 QD | 18 | 1065.6 (699.2) | 65.6% | 26.3 (15.6-56.1) | 3525.3 (1459.1) | 41.4% | 32.7 (17.2-54.5) |
Lopinavir (boosted with ritonavir) | 400 BID | 16 | 6370.0 (2846.4) | 44.7% | 23.8 (12.8-75.8) | 8991.3 (2953.3) | 32.8% | 14.0 (12.3-21.7) |
Lopinavir (boosted with ritonavir) | 800 QD | 4 | 5356.2 (3882.3) | 72.5% | 63.4 (35.2- 115) | 11151.3 (4433.2) | 39.8% | 15.6 ( 7.4-28.4) |
Efavirenz | 600 QD | 16 | 2196.9 (1209.2) | 55.0% | 17.7 (10.5-25.1) | 3929.4 (2060.6) | 52.4% | 15.5 (12.8-27.9) |
Nevirapine | 200 BID | 11 | 5693.6 (2586.8) | 45.4% | 13.9 (10.2-27.8) | 6490.9 (2454.9) | 37.8% | 10.7 ( 7.8-19.6) |
Nevirapine | 400 QD | 8 | 5027.9 (2867.2) | 57.0% | 21.3 (12.1-44.9) | 6924.4 (2761.1) | 39.9% | 22.8 ( 8.3-53.8) |